### **Overview** Sakar Healthcare Limited, established in 2004 by entrepreneur Mr. Sanjay Shah and headquartered in Changodar, Ahmedabad, Gujarat, is a rapidly evolving Indian pharmaceutical company with a strong focus on oncology, antibiotics, and general formulations. From its origins as a contract manufacturer of oral liquid formulations, the company has strategically transformed into a **vertically integrated, research-driven pharmaceutical player**, recognized among India’s **Top 10 oncology drug manufacturers (India Pharma Outlook, 2024)**. Sakar operates **EU-GMP and WHO-GMP certified manufacturing facilities** across 39,121 sq. meters in Bavla and Changodar, Gujarat, producing a wide array of dosage forms including oral solids, liquids, sterile injectables, lyophilized products, dry powder injections, and high-potency APIs. --- ### **Core Business Segments & Diversified Revenue Model** Sakar Healthcare follows a **multi-pronged business strategy**, ensuring stable and scalable revenue streams: 1. **Contract Development & Manufacturing (CDMO/CMO)** - Partners with leading multinational and Indian pharmaceutical companies including **Zydus Lifesciences, Glenmark, Intas, Emcure, Dr. Reddy’s, Biocon, and Ferring Pharmaceuticals**. - Offers **end-to-end services** from R&D and process optimization to regulatory dossier preparation and commercial manufacturing under **global compliance standards (EMA, USFDA)**. - Serves as a **premium CDMO in oncology** with integrated API capabilities, supporting tech transfer, bioequivalence studies, and large-scale production. 2. **Own-Brand Exports** - Exports own-branded formulations to **over 60 countries** across APAC, Latin America, Africa, CIS, Europe, and MENA. - Approximately **70% of exports are under the company’s own brands**, enhancing margin capture and brand equity. - Key export markets include the **UK, EU, Canada, Africa, Latin America, Southeast Asia, and GCC**. 3. **Technology Transfer & Licensing (CRAMS, LSA, Profit Sharing)** - Engages in **co-development, loan licensing (LSA), out-licensing, and profit-sharing models** globally. - Has executed **multiple technology transfers** for major Indian pharma firms and developed **32+ eCTD/CTD dossiers** compliant with EU/US regulations. 4. **Pipeline & Product Development** - Focuses on **non-infringing patent products and complex generics**, particularly in high-barrier therapeutic areas like oncology. - Leverages **proprietary processes and green chemistry** to differentiate products and reduce environmental impact. --- ### **Oncology: The Strategic Growth Driver** Oncology is the **core of Sakar’s transformation** and long-term value creation, positioning the company as a **global niche player in anti-cancer therapeutics**. #### **Key Oncology Highlights (as of Nov 2025):** - **Vertically Integrated API-to-FDF Facility** in Bavla, Gujarat: - One of the **few research-driven, API-integrated oncology plants in India**. - EU-GMP and WHO-GMP certified with **OEL Level 4 containment** for safe handling of cytotoxic compounds. - Annual capacities: - **12.3 MT of oncology APIs** - **97 million tablets & 29 million capsules** - **13 million vials of sterile injectables** - **9,600 kg high-potency API capacity** - **Regulatory Milestones**: - **11 granted Marketing Authorizations (MAs)** globally, including **5 in Europe (Bulgaria, Bosnia)** and 5 in emerging markets (SE Asia, Latin America). - Approved products: **Carboplatin, Docetaxel, Irinotecan, Gemcitabine (lyophilized), Tamoxifen, Imatinib, Capecitabine**, etc. - Targets multiple cancers: ovarian, lung, breast, prostate, colorectal, blood cancers (leukemia), multiple myeloma. - **Intellectual Property & Innovation**: - **First granted patent (2024)**: Process patent for **Imatinib (Indian Patent No. 488161)** — a tyrosine kinase inhibitor for chronic myelogenous leukemia. - Developing **21 in-house oncology APIs**, with **16 regulatory confirmations** and **7 pending CEP applications**. - Co-developing **non-infringing, patent-protected oncology molecules** with partners in Greece and Switzerland. - **Advanced Drug Delivery Platforms**: - **Liposomal technologies**: Commercialized **Pegylated Liposomal Doxorubicin (Doxil®/Caelyx® equivalent)**; also developed **Daunorubicin, Paclitaxel, and Tretinoin** in liposomal form. - **HME (Hot-Melt Extrusion)**: Enhancing solubility of poorly soluble drugs like **apalutamide, enzalutamide, and olaparib**. - **Flow Chemistry (Vapourtech, UK)**: For improved yield, safety, and sustainability in complex synthesis. - **Regulatory Pipeline**: - **32 dossiers ready for launch**, with **80+ dossiers submitted globally**. - Awaiting **additional MA approvals** in EU and regulated markets, expected within the next few quarters. - **292+ product registrations**, with **over 40 active discussions** for new supply and out-licensing partnerships. --- ### **Manufacturing & Technology** - **4 state-of-the-art manufacturing units** producing over **22 therapeutic categories** (including anti-infectives, PPIs, antifungals, anticoagulants). - **Advanced Equipment & Technologies**: - **TOFFLON lyophilizers** (automated ORABS), **Di-Dietrich glass reactors**, **GEA granulation lines**, **Lipex Flow Pump for liposomal extrusion**. - Compliance with **green chemistry principles**, **zero liquid discharge (ZLD)**, and **solar power systems**. - **In-House Capabilities**: - Full **EU/US FDA-compliant CTD dossier development**. - Bioequivalence studies through EMA/USFDA-approved CROs. - **Analytical, formulation, and R&D labs** integrated within the site. --- ### **Global Market Strategy** Sakar employs a **region-specific commercial model** to maximize market access and profitability: | Region | Strategy | |-------|--------| | **EU & UK** | Licensing & supply for oral solids | | **MENA** | CDMO for oncology oral liquids | | **Africa** | MAH & distribution for liquid injections | | **Latin America & Canada** | Profit-sharing for lyophilized injections | | **APAC** | Co-development and tech transfer for bulk drugs | | **CIS** | Focus on oncology APIs | - Active partnerships with **75+ international firms**, including **Accord Healthcare, Ferring, PharOS, Dr. Reddy’s, Biocon, Emcure**, and top-20 pharma companies. - **49 active agreements** covering **277 oncology SKUs** under CDMO, CMO, out-licensing, and profit-sharing models. --- ### **Strategic Milestones & Recognition** - **Mar 2024**: EU GMP approval for oral solids and injectables at Bavla oncology unit. - **Apr 2019**: Migrated from NSE SME Platform to **Main Board (NSE: SAKAR)**. - **Aug 2024**: Oncology unit recognized by **DSIR** for R&D excellence. - **2024**: Ranked **Top 10 Oncology Drug Manufacturer in India** by *India Pharma Outlook*. --- ### **Leadership & Operations** - **Founder & Chairman**: Mr. Sanjay Shah — over two-decade-long experience in pharmaceuticals. - **Strong Customer Base**: Top 5 customers (engaged >5 years) account for **45.4% of FY21 revenue**, reflecting deep client integration and reliability. - **Workforce**: Over **300 employees**; skilled scientific and regulatory teams. ---